HIV Treatments in DevelopmentFeatures

Islatravir Is Potent and Long-Lasting -- and May Be Having an Identity Crisis

#6 in TheBodyPro's Top 10 HIV Clinical Developments of 2019

Islatravir photo illo
Photo illustration: Remedy Health Media; Background and paper tear: iStock

    Islatravir Phase 2 Results: 10th IAS Conference on HIV Science. (2019). "Tolerability, safety and efficacy of MK-8591 at doses of 0.25 to 2.25 mg QD, in combination with doravirine and lamivudine through 24 weeks in treatment-naïve adults with HIV-1 infection."

    David Alain Wohl, M.D.

    David Alain Wohl, M.D.

    David Alain Wohl, M.D., is a professor at the University of North Carolina, site leader of the UNC AIDS Clinical Trials Unit at Chapel Hill, director of the North Carolina AETC, and co-director of HIV services for the NC state prison system.